Estimates down on delayed margin recovery

Jm Ab (Buy, TP: SEK170.00) - Passing the trough

Q1 EBIT was 4% below our estimate and Infront consensus, while EPS fell well short in percentage terms due to a low nominal figure. KPIs did not recover as much as we expected, although JM reiterated its target to increase housing starts to 3,800 units p.a., citing macroeconomic conditions as a key factor. Given the current market outlook, we believe the company has passed the trough on EPS, as we expect starts and sales to recover in late 2025 and 2026. We reiterate our BUY and target price of ...

Margins continue to surprise negatively

Good value

Europris (Buy, TP: NOK90.00) - Well-equipped for a harsher climate

Q1 earnings were below expectations, partly due to negative currency hedging effects in Norway and Sweden, and continued weakness in Sweden. However, we believe Europris is well-positioned for the current market climate and expect a successful turnaround in Sweden by 2028. We reiterate our BUY as we continue to find the valuation attractive, but have cut our target price to NOK90 (95) on lowered estimates.

Sweden fuels the unknown

EBIT below driven by SWE and GP

EBIT -37m vs cons +6m on lower sales in SWE and lower group gross profit. Gross profit hit by unrealized FX as the NOK has strengthened.

Mixed upside potential, despite market recovery expectations

Pent-up demand and falling interest rates remain the backbone for newbuild recovery expectations. However, as the recovery has not yet started, property developers screen as the most attractive long-term, but visibility remains mixed. Diversified construction companies are more attractive on near-term P/Es, although many seem to be fully valued on solid share-price performance over the past six months. We maintain a neutral sector view; NCC and Skanska are our top picks.

Built for resilience

Jm Ab (Buy, TP: SEK170.00) - BUY on the dip

JM’s share price has been volatile over the past three years, trading in waves on recovery expectations. As the Swedish residential market has yet to recover, expectations have recently fallen further, and the stock has reached old lows. However, we expect a market recovery in late-2025 and 2026, and we believe this has created an attractive entry point. KPIs (unit sales and unit starts) are our Q1 focus point, as profits are still affected by cycle lows and a trailing profit recognition. We hav...

Europris (Buy, TP: NOK95.00) - Strong Q1 masked by late Easter

We are positive ahead of Q1, expecting results in line with consensus and on a par with last year, on solid LFL growth in Norway despite a late Easter. We reiterate our BUY and NOK95 target price, as we continue to find the valuation attractive relative to peers on earnings multiples excluding ÖoB’s long-term value potential.

JM AB: 2 directors

Two Directors at JM AB bought 2,267 shares at between 159.388SEK and 168.400SEK. The significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...

Recovery delayed again

Jm Ab (Hold, TP: SEK170.00) - Set to be a slow recovery

The Q4 results were a mixed bag, with revenues beating expectations, boosted by project starts, impairments resulting in an EBIT miss, and mixed KPIs. However, we believe the Q4 spike in unsold inventory (new all-time high) likely poses JM’s biggest challenge entering 2025, as it could hold back new starts by tying up capital. We reiterate our HOLD and SEK170 target price; we still expect a profit recovery to take longer than is reflected in the share price and see a better risk/reward elsewhere...

Share down on inventory and CF

Europris (Buy, TP: NOK95.00) - Norway leading the way

Q4 earnings were above expectations on a strong performance by Norway, while Sweden was soft, primarily due to higher costs, reflecting the ongoing turnaround. We reiterate our BUY and have raised our target price to NOK95 (85) on minor positive estimate revisions. At our target price, Europris would be trading at a 2025e P/E of 15.5x adjusted for ÖoB (which we estimate could add >NOK1 to EPS by 2028).

A tale of two markets

Better, Norway very solid on high GM

EBIT 6% better, Norway particularly strong on higher margins. Somewhat more optimistic outlook

Steady, but no spark

Wide peer valuation range on market recovery expectations

Various waves of expectations for a recovery in newbuild markets have led to volatility in the sector, but an upwards share-price trend overall. Although we still await proof the new-volume market (both residential and commercial) is recovering, consensus is fuelled by falling rates. However, trailing profits under IFRS valuations are record-wide. We maintain a neutral sector view and stock-picking approach.